-
公开(公告)号：EP3702447A1
公开(公告)日：2020-09-02
申请号：EP19218292.1
申请日：2016-10-20
申请人： Kite Pharma, Inc. , The United States of America, as represented by the Secretary, Department of Health and Human Services
IPC分类号： C12N5/0783 , A61K35/17
摘要： Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
-
公开(公告)号：EP3364969A1
公开(公告)日：2018-08-29
申请号：EP16858247.6
申请日：2016-10-20
申请人： Kite Pharma, Inc. , The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
IPC分类号： A61K31/436 , C12N5/078 , C12N5/0783
CPC分类号： A61K35/17 , A61K39/0011 , A61K2039/5156 , A61K2039/5158 , A61K2039/572 , C07K14/7051 , C12N5/0636 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/727 , C12N2506/11
摘要： Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
-
公开(公告)号：EP3893899A2
公开(公告)日：2021-10-20
申请号：EP19836733.6
申请日：2019-12-11
申请人： Kite Pharma, Inc.
IPC分类号： A61K35/17 , A61K39/00 , A61P35/02 , C07K14/725 , C07K16/28
-
-
搜索结果
3 条记录 (耗时 0.019 秒)
